Safety and effectiveness of SGLT2 inhibitors in a UK population with type 2 diabetes and aged over 70 years: an instrumental variable approach.
Laura M GüdemannKatie G YoungNicholas J M ThomasRhian HopkinsRobert ChallenAngus G JonesAndrew T HattersleyEwan R PearsonBeverley M ShieldsJack BowdenRaphael SonabendAndrew P McGovernnull nullPublished in: Diabetologia (2024)
Causal analysis suggests SGLT2i are effective in adults aged ≥70 years, but increase risk for genital infections and diabetic ketoacidosis. Our study extends RCT evidence to older adults with type 2 diabetes.